Compositions and methods for treating multiple sclerosis

Patent metadata

Field	Value
Publication number	US-11998547-B2
Application number	US-202117189870-A
Country	US
Kind code	B2
Filing date	Mar 2, 2021
Priority date	Feb 26, 2015
Publication date	Jun 4, 2024
Grant date	Jun 4, 2024

Abstract

The present disclosure relates to compounds and compositions that inhibit the NLRP3 inflammasome, for example, a compound according to formula I

wherein
R 1 is C 1-4 alkyl; and
R 2 is H or C 1-4 alkyl, provided that when R 2 is H. R 1 is not CH 3 .

Also disclosed are methods for treating multiple sclerosis using the compounds and compositions.

First claim

What is claimed is:

1. A method of treating a condition selected from Parkinson's disease, Alzheimer's disease, and multiple sclerosis comprising administering to a subject having said condition a compound having a structure selected from:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the compound has a structure selected from:

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the compound has a structure selected from:

or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the compound has a structure selected from:

or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 , wherein the method comprises administering a composition comprising a pharmaceutically acceptable carrier and the compound.

7. The method of claim 1 , wherein the treating comprises an active treatment, or a causal treatment.

8. The method of claim 5 , wherein the method comprises administering a composition comprising a pharmaceutically acceptable carrier and the compound.

9. The method of claim 1 , wherein the treating comprises a palliative treatment, or a supportive treatment.

10. The method of claim 1 , wherein the condition is Parkinson's disease.

11. The method of claim 1 , wherein the condition is Alzheimer's disease.

12. The method of claim 1 , wherein the condition is multiple sclerosis.

13. A method of treating amyotrophic lateral sclerosis, comprising administering to a subject having amyotrophic lateral sclerosis a compound having a structure selected from:

or a pharmaceutically acceptable salt thereof.

14. The method of claim 13 , wherein the compound has a structure selected from:

or a pharmaceutically acceptable salt thereof.

15. The method of claim 13 , wherein the compound has a structure selected from:

or a pharmaceutically acceptable salt thereof.

16. The method of claim 13 , wherein the compound has a structure selected from:

or a pharmaceutically acceptable salt thereof.

17. The method of claim 13 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

18. The method of claim 13 , wherein the method comprises administering a composition comprising a pharmaceutically acceptable carrier and the compound.

19. The method of claim 13 , wherein the treating comprises an active treatment, or a causal treatment.

20. The method of claim 17 , wherein the method comprises administering a composition comprising a pharmaceutically acceptable carrier and the compound.

21. The method of claim 13 , wherein the treating comprises a palliative treatment, or a supportive treatment.

Assignees

• Univ Kentucky Res Found

Inventors

• Ambati Jayakrishna
• Fowler Benjamin
• Ambati Kameshwari

Classifications

• C07D411/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• A61K31/506 Primary

  not condensed and containing further heterocyclic rings · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title